Lineage Cell Therapeutics (LCTX) Q4 2024 earnings summary

Executive summary

• OpRegen, the lead candidate for dry AMD, continues to progress in the Phase IIa GALET Study managed by Roche and Genentech, with recent RMAT designation and ongoing site expansion, supported by positive 24-month visual acuity data and FDA RMAT designation.

• Three-year data from the earlier Phase I/IIa trial show durable anatomical and functional vision improvements, with BCVA gains persisting and outperforming both standard therapy and untreated controls.

• Initiated OPC1 device delivery study for spinal cord injury, with a new delivery device and improved manufacturing process being tested in the DOSE study, targeting both safety and functional outcomes in chronic patients.

• Significant investments in scalable GMP manufacturing have positioned the company as a leader in allogeneic cell therapy production, aiming for millions of doses per batch.

• Strengthened balance sheet with $44 million in gross proceeds from two financings, with potential for an additional $36 million upon warrant exercise.

Financial highlights

• Year-end cash, cash equivalents, and marketable securities totaled $47.8 million as of December 31, 2024, with an additional $5.5 million received in January, extending runway into Q1 2027.

• Q4 2024 revenues were $2.9 million, up $0.8 million year-over-year, primarily from increased collaboration revenue with Roche.

• Q4 operating expenses were $7.8 million, down $0.4 million year-over-year, with R&D expenses decreasing by $0.5 million.

• Q4 net loss was $3.3 million ($0.02/share), improved from $4.8 million ($0.03/share) in Q4 2023.

• Full-year 2024 net loss was $18.6 million ($0.09/share), improved from $21.5 million ($0.12/share) in 2023.

Outlook and guidance

• Cash runway supports operations into Q1 2027, with potential for an additional $36 million from milestone warrants tied to OpRegen clinical progress.

• Anticipates advancing internal programs through key milestones in 2025, including the DOSED clinical study for OPC1 and further development of Resonance.

• Awaiting potential advancement of OpRegen to a controlled clinical trial, which could trigger further capital inflow and program milestones.

• OPC1 program enhancements and a larger trial are planned, pending completion of device, manufacturing, and trial design improvements.